Brain cancer treatment tailored to each Child's tumor type shows promise
NCT ID NCT01878617
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This phase 2 trial tests a personalized approach to treating medulloblastoma, a common childhood brain cancer. Instead of using a one-size-fits-all treatment, doctors assign therapy based on the tumor's molecular subtype (WNT, SHH, or other) and clinical risk (low to high). The goal is to see if lower doses of radiation and chemotherapy can work for low-risk patients, reducing long-term side effects, while adding targeted drugs for higher-risk patients. About 660 children and young adults are enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alberta Children's Hospital
Calgary, Alberta, T3B 6A8, Canada
-
Arnold Palmer Hospital for Children
Orlando, Florida, 32806, United States
-
Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, H3T 1C5, Canada
-
Children's Hospital and Clinics of Minnesota
Minneapolis, Minnesota, 55102, United States
-
Children's Hospital at Westmead
Westmead, New South Wales, 2145, Australia
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
Cook Children's Medical Center
Fort Worth, Texas, 76104, United States
-
Duke Children's Hospital and Health Center
Durham, North Carolina, 27710, United States
-
Lucille Packard Children's Hospital at Stanford University Medical Center
Palo Alto, California, 94304, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Perth Children's Hospital
Perth, Western Australia, 6008, Australia
-
Queensland Children's Hospital
Brisbane, Queensland, 4029, Australia
-
Rady Children's Hospital
San Diego, California, 92123, United States
-
Royal Children's Hospital, Melbourne
Melbourne, Victoria, 3052, Australia
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
Starship Children's Hospital
Auckland, 1142, New Zealand
-
Sydney Children's Hospital
Randwick, New South Wales, 2031, Australia
-
Texas Children's Cancer Center
Houston, Texas, 77030-2399, United States
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
University of Florida
Gainesville, Florida, 32611, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Yale University
New Haven, Connecticut, 06520, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy and chemotherapy (cyclophosphamide, cisplatin)
What this could lead to
If successful, this approach could tailor treatment for medulloblastoma, reducing side effects for low-risk patients and improving outcomes for high-risk patients.
What could go wrong
This is a phase 2 trial, so results are not yet confirmed. The personalized approach may not work for all subtypes, and reduced radiation could increase recurrence risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.